Active Ingredient History
GENISTEIN is an isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in Felmingia vestita, which is a plant traditionally used against worms. It has also been demonstrated to be effective against intestinal parasites such as the common liver fluke, pork trematode and poultry cestode. Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women. Genistein can be found in food sources such as tofu, fava beans, soybeans, kudzu, and lupin. It is also present in certain cell cultures and medicinal plants. NCATS
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute Radiation Syndrome (Phase 1)
Adenocarcinoma (Phase 1/Phase 2)
Bone Diseases (Phase 2)
Bone Diseases, Metabolic (Phase 2/Phase 3)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Cardiovascular Diseases (Phase 2)
Colonic Neoplasms (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Coronary Artery Disease (Phase 2/Phase 3)
Coronary Disease (Phase 2)
COVID-19 (Phase 2)
Cystic Fibrosis (Phase 2)
Depression (Phase 2)
Endometrial Hyperplasia (Phase 2)
Endometrial Neoplasms (Phase 1)
Heart Diseases (Phase 2)
Hodgkin Disease (Phase 2)
Kidney Neoplasms (Phase 1/Phase 2)
Lung Neoplasms (Phase 1/Phase 2)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Medulloblastoma (Phase 2)
Melanoma (Phase 1/Phase 2)
Menopause (Phase 2/Phase 3)
Metabolic Syndrome (Phase 3)
Myocardial Ischemia (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors, Primitive (Phase 2)
Osteoporosis (Phase 2/Phase 3)
Pain (Phase 1/Phase 2)
Pancreatic Neoplasms (Phase 2)
Postmenopause (Phase 2)
Prostatic Neoplasms (Phase 2/Phase 3)
Pulmonary Fibrosis (Phase 2)
Rectal Neoplasms (Phase 1/Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Sepsis (Phase 4)
Urinary Bladder Neoplasms (Phase 2)
Wilms Tumor (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue